1. Tan, B.K., et al. (2014). Circulatory changes of the novel adipokine adipolin/CTRP12 in response to metformin treatment and an oral glucose challenge in humans. Clinical endocrinology, 81(6): 841-846.
2. Enomoto, T., et al., (2011). Adipolin/C1qdc2/CTRP12 protein functions as an adipokine that improves glucose metabol ism. Journal of Biological Chemistry, 286(40): 34552-34558.
3. Yang, Q., et al. (2005). Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature, 436(7049): p. 356-362.
4. Peterson, J.M., Z. Wei, and G.W. Wong. (2010). C1q/TNF-related protein-3 (CTRP3), a novel adipokine that regulates hepatic glucose output. Journal of Biological Chemistry, 285(51): 39691-39701.
5. Frydelund-Larsen, L., et al. (2007). Visfatin mRNA expression in human subcutaneous adipose tissue is regulated by exercise. American Journal of Physiology-Endocrinology and Metabolism, 292(1): p. E24-E31.
6. Tan, B.K., et al. (2013). Metformin increases the novel adipokine adipolin/CTRP12: role of the AMPK pathway. Journal of Endocrinology, 219(2): p. 101-108.
7. Wei, Z., et al. (2012). C1q/TNF-related protein-12 (CTRP12), a novel adipokine that improves insulin sensitivity and glycemic control in mouse models of obesity and diabetes. Journal of Biological Chemistry, 287(13): p. 10301-10315.
8. Shehzad, A., et al. (2012). Adiponectin: regulation of its production and its role in human diseases. Hormones (Athens), 11(1): p. 8-20.
9. Choi, K., et al. (2007). Effect of exercise training on plasma visfatin and eotaxin levels. European Journal of Endocrinology, 157(4): p. 437-442.
10. Arner, P. (2006). Visfatin-a true or false trail to type 2 diabetes mellitus. The Journal of clinical endocrinology and metabolism, 91(1): p. 28.
11. Balducci S, Zanuso S, Nicolucci A, et al. (2010). Anti-inflammatoryeffect of exercise training in subjects with type 2 diabetes and the metabolic syndrome isdependenton exercise modalities and independent of weightloss. Nutr Metab Cardiovasc Dis, 20(8): 608-17.
12. Kawamata Y, Imamura T, Babendure JL, et al. (2007). Tumor necrosis factor receptor-1 can function through a G alphaq/11-betaarrestin- 1 signaling complex. J Biol Chem, 282(39): 28549-56.
13. Ouchi N, Higuchi A, Ohashi K, et al. (2010). Sfrp5 is an anti-inflammatory adipokine that modulates metabolic dysfunction in obesity. Science, 329:454-457.
14. CnopM, FoufelleF, VellosoLA. (2012). Endoplasmicreticulum stress, obesity and diabetes. Trends Mol Med, 18(1): 59-68.
15. Hotamisligil GS, Shargill NS, Spiegelman BM. (1993). Adipose expression of tumor necrosisfactor-alpha: direct role in obesity-linked insulin resistance. Science, 259: 87-91.
16. Henriksen EJ. (2002). Effects of acuteexercise and exercise training on insulin resistance. J Appl Physiol, 93(2): 788-96.
17. Brooks N, Layne JE, Gordon PL, et al. (2007). Strength trainingimproves muscle quality and insulin sensitivity inHispanic older adults with type 2 diabetes. Int JMed Sci, 4(1): 19-27.
18. Rodrigues B, Figueroa D, Mostarda C, et al. (2007). Maxima exercise test is a useful method for physical capacity and oxygen consumption determination in streptozotocin-diabetic rats. Cardiovascular Dialectology, 6(38):125-131.